Launching the PREFER Recommendations

On April 28 2022, the PREFER project will launch a set of recommendations for how and when it is best to perform and include patient preferences in decision making during the medical product life cycle. The recommendations are the result of a five-year effort from public and private partners. Patient stakeholders have been involved at every level of the project, co-creating a set of recommendations that can support the development of guidelines for structured patient input into decision-making for the pharmaceutical industry, regulatory authorities, health technology assessment bodies and reimbursement agencies!

(Image removed)

We will share the take-home messages from the PREFER Recommendations, explaining when and why structured input from patient preference studies can support decision making. We will describe the PREFER framework, explaining how to do a preference study, how to identify and involve key stakeholders, how to pick the right method for your research questions, explore the impact of psychological constructs on preference heterogeneity, and how different approaches and educational materials can support patient’s understanding, giving you more reliable results.

The event is open to everyone with a stake in the decisions that are made along the medical product life-cycle: We invite anyone and everyone who is or will become a patient. All those making decisions from drug discovery to post marketing of medicines. The researchers that drive innovation, the companies that develop medicines, the authorities that approve them, and those that decide what becomes available to patients in different countries and health care systems: the health technology assessors, reimbursement agencies and payers. Everyone interested in patient engagement. Along with the entire preference research community!

Title: Finding out what patients PREFER: Why, when and how to assess and use patient preferences in medical product decision-making
When: 28 April, 14-16 CET
What: Open online event

More information & registration (Link removed)





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).